China Industrial Asset Management Leads $40M Series C1 Round In Chinese Cancer Immunotherapy Company

Chinese cancer immunotherapy company Shanghai Cell Therapy Group Co. has raised RMB275 million (US$39.60 million) in series C1 round of financing from private equity firm China Industrial Asset Management Limited. 

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets